New prognostic laboratory parameters and use of intravenous immunglobulin G replacement for severe H1N1 infections

Basit Öğe Kaydı
dc.contributor.authorGokturk, B.
dc.contributor.authorPekcan, S.
dc.contributor.authorEmiroglu, Keser M.
dc.contributor.authorKirac, M.
dc.contributor.authorKeles, S.
dc.contributor.authorGuner, Sn
dc.contributor.authorArtac, H.
dc.date.accessioned2024-02-23T14:45:01Z
dc.date.available2024-02-23T14:45:01Z
dc.date.issued2013
dc.departmentNEÜen_US
dc.description15th Biennial Meeting of the European-Society-for-Primary-Immunodeficiency (ESID) -- OCT 03-06, 2012 -- Florence, ITALYen_US
dc.description.abstractThe appropriate treatment of severe pandemic H1N1 influenza, which was first identified in April 2009 in Mexico, is insufficient, especially in immunodeficient patients. We aimed to evaluate the features and prognostic factors of children with H1N1, and whether intravenous immunoglobulin G (IVIG) replacement can aid in facilitating a better outcome. Fifty-five hospitalized children with laboratory-confirmed H1N1 were evaluated retrospectively. The median age was 71 (1-216) months; and 65.4% had one or more underlying disorders. Thirty percent of the evaluated patients had one of the primary immunodeficiency disorders. Respiratory complications were seen in 72.7% of children. The mortality rate was 9%. Surprisingly, none of the six patients with primary immunodeficiency who were on regular IVIG replacement required intensive care unit admission or died. Eighty-three percent of patients who needed mechanical ventilation (p<0.001) and 27.7% of patients who needed oxygen support (p=0.002) died. The mortality rate of patients who admitted with neurological symptoms was higher (p=0.012, odds ratio: 17.25, confidence interval: 2.19-135.4). The mortality rate was significantly higher in patients with thrombocyte counts <165500/mm(3) (sensitivity: 79.6%, specificity: 83.3%) and with alanine aminotransferase (ALT) levels >50.5 U/L (sensitivity: 83.3%, specificity: 89.8%). Our study is important as it is the first to show the course in primary immunodeficient children with H1N1 infection who were on regular IVIG replacement. Thrombocytopenia, high ALT, neurologic symptoms, and hypoxia were detected as poor prognostic factors.en_US
dc.description.sponsorshipEuropean Soc Primary Immunodeficiency (ESID),Int Nursing Grp Immunodeficiencies (INGID),Int Patient Org Primary Immunodeficiencies (IPOPI)en_US
dc.identifier.endpage13en_US
dc.identifier.isbn978-88-7587-666-1
dc.identifier.startpage9en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12452/17211
dc.identifier.wosWOS:000324375200003en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherMedimond S R Len_US
dc.relation.ispartofProceedings Of The 15th Meeting Of The European Society Immunodeficiencies (Esid)en_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[Keyword Not Available]en_US
dc.titleNew prognostic laboratory parameters and use of intravenous immunglobulin G replacement for severe H1N1 infectionsen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu